Waldenström Macroglobulinemia: Clinico-pathological Profile and Treatment Outcomes of Patients from a Tertiary Care Centre of North India


Waldenstorms Macroglobulinemia (WM) is a rare mature B cell neoplasm characterized by a lymphoplasmacytic lymphoma and an IgM monoclonal protein. It is managed by Rituximab based chemotherapy. A single-centre retrospective study was carried out to analyse the clinical presentation, laboratory features, and treatment outcomes of all consecutive patients of WM, diagnosed over a period of 86 months. First-line treatment regimens included RCD (Rituximab/Cyclophosphamide/Dexamethasone), BDR (Bortezomib /Dexamethasone/ Rituximab) and (Lenalidomide/Dexamethasone). A total of 26 patients of WM were diagnosed during this period, with a median age of 65 years. Majority (89%) of these patients were of intermediate (47%) to high risk (42%). An overall response rate of 76.4% was achieved. RCD was found superior to BDR in terms of treatment response. For those who required 2nd line chemotherapy, the median time to next treatment was 22 months. To conclude, a late presentation and higher risk categories were common in our cohort of patients. Treatment outcome was comparable to those reported in western literature. RCD regimen was found to be a better treatment option in terms of overall survival.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2


  1. 1.

    Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, Kwak L, Rustveld L, Du XL, Wang M (2012) Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 118:3793–3800

    Article  Google Scholar 

  2. 2.

    Brandefors L, Kimby E, Lundqvist K, Melin B, Lindh J (2016) Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and hematological malignancies—a population-based study from northern Sweden. Acta Oncol 55:91–98

    CAS  Article  Google Scholar 

  3. 3.

    Stein HM-HH, Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H et al (2008) Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow S, Campo E, Harris NL et al (eds) International Agency for Research on Cancer. WHO classification of tumors of hematopoietic and lymphoid tissue. 4. World Health Organization, Geneva, pp 180–182

    Google Scholar 

  4. 4.

    Gertz MA (2019) Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 94(2):266–276. https://doi.org/10.1002/ajh.25292

    Article  PubMed  Google Scholar 

  5. 5.

    Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP (2015) Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology, and end results database. Br J Haematol 169(1):81–89

    Article  Google Scholar 

  6. 6.

    Kristinsson SY, Eloranta S, Dickman PW et al (2013) Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 88(1):60–65

    Article  Google Scholar 

  7. 7.

    Oza A, Rajkumar SV (2015) Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J 5(3):e394. https://doi.org/10.1038/bcj.2015.28

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Dimopoulos MA, Anagnostopoulos A (2005) Waldenstrom’s macroglobulinemia. Best Pract Res Clin Haematol 18:747–765

    CAS  Article  Google Scholar 

  9. 9.

    Bjorkholm M, Johansson E, Papamichael D et al (2003) Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom’s macroglobulinemia: a two-institution study. Semin Oncol 30:226–230

    CAS  Article  Google Scholar 

  10. 10.

    Meletios A (2019) Dimopoulos, Efstathios Kastritis; How I treat Waldenström macroglobulinemia. Blood 134(23):2022–2035

    Article  Google Scholar 

  11. 11.

    Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al (2012) MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 367(9):826–833

    CAS  Article  Google Scholar 

  12. 12.

    Buske C, Sadullah S, Kastritis E et al (2018) European Consortium for Waldenström’s Macroglobulinemia. Treatment and outcome patterns in European patients with Waldenström’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol 5(7):e 299-e 309

    Article  Google Scholar 

  13. 13.

    Owen RG, Kyle RA, Stone MJ et al (2013) Response assessment in Waldenström macroglobulinaemia: update from the VIth international workshop. Br J Haematol 160(2):171–176

    Article  Google Scholar 

  14. 14.

    Patkar N, Subramanian PG, Deshpande P, Ghodke K, Tembhare P, Mascarenhas R, Muranjan A, Chaudhary S, Bagal B, Gujral S, Sengar M, Menon H (2015) MYD88 mutant lymphoplasmacyticlymphoma/Waldenströmmacroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Leuk Lymphoma 56(2):420–425

    CAS  Article  Google Scholar 

  15. 15.

    Gavriatopoulou M, García-Sanz R, Kastritis E et al (2017) BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood 129(4):456–459

    CAS  Article  Google Scholar 

  16. 16.

    Ioakimidis L, Patterson C, Hunter Z et al (2009) Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 9(1):62–66

    CAS  Article  Google Scholar 

  17. 17.

    Dimopoulos MA, Anagnostopoulos A, Kyrtsonis M-C et al (2007) Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344–3349

    CAS  Article  Google Scholar 

  18. 18.

    Treon SP, Hunter Z, Branagan AR (2005) CHOP plus rituximab therapy in Waldenström’s macroglobulinemia. Clin Lymphoma 5(4):273–277

    CAS  Article  Google Scholar 

  19. 19.

    Kastritis E, Gavriatopoulou M, Kyrtsonis MC et al (2015) Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood 126(11):1392–1394

    Article  Google Scholar 

  20. 20.

    Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M et al (2013) Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and Rituximab (BDR): long-term results of a phase 2 study of the European myeloma network (EMN). Blood 122:3276–3282

    CAS  Article  Google Scholar 

  21. 21.

    Treon SP, Hanzis C, Manning RJ et al (2011) Maintenance rituximab is associated with improved clinical outcomes in Rituximab naïve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 154(3):357–362

    CAS  Article  Google Scholar 

  22. 22.

    Morel P, Duhamel A, Gobbi P et al (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113(18):4163–4170. https://doi.org/10.1182/blood-2008-08-174961

    CAS  Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Sanjeev.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kumar, S., Sanjeev, Rahman, K. et al. Waldenström Macroglobulinemia: Clinico-pathological Profile and Treatment Outcomes of Patients from a Tertiary Care Centre of North India. Indian J Hematol Blood Transfus (2020). https://doi.org/10.1007/s12288-020-01382-w

Download citation


  • Waldenstorms macroglobulinemia
  • Clinicopathological features
  • Treatment outcome